Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine ...
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia ...
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
Austedo: Regaining Control Over Uncontrolled Movements in ...
Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
AUSTEDO® XR: Tardive Dyskinesia and Huntington's Chorea …
AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea. See safety info including Boxed Warning.
Tardive Dyskinesia (TD) Resources | AUSTEDO XR ...
Resources for each step of the treatment journey with AUSTEDO XR Teva is committed to supporting your patients with tardive dyskinesia (TD) and their care partners.
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine ...
Feb 17, 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.